Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 463

1.

Outcomes in adult critically Ill cancer patients with and without neutropenia: a systematic review and meta-analysis of the Groupe de Recherche en Réanimation Respiratoire du patient d'Onco-Hématologie (GRRR-OH).

Bouteloup M, Perinel S, Bourmaud A, Azoulay E, Mokart D, Darmon M.

Oncotarget. 2016 Sep 21. doi: 10.18632/oncotarget.12165. [Epub ahead of print] Review.

2.

Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety.

La Torre G, Mannocci A, Colamesta V, D'Egidio V, Sestili C, Spadea A.

Mediterr J Hematol Infect Dis. 2016 Sep 1;8(1):e2016044. doi: 10.4084/MJHID.2016.044. eCollection 2016. Review.

3.

Telomerase Activation in Hematological Malignancies.

Ropio J, Merlio JP, Soares P, Chevret E.

Genes (Basel). 2016 Sep 7;7(9). pii: E61. doi: 10.3390/genes7090061. Review.

4.

Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy.

Sánchez-Ramón S, Dhalla F, Chapel H.

Front Immunol. 2016 Aug 22;7:317. doi: 10.3389/fimmu.2016.00317. eCollection 2016. Review.

5.

Clostridium tertium in neutropenic patients: case series at a cancer institute.

Shah S, Hankenson J, Pabbathi S, Greene J, Nanjappa S.

Int J Infect Dis. 2016 Aug 26;51:44-46. doi: 10.1016/j.ijid.2016.08.013. [Epub ahead of print] Review.

6.

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.

Pinilla-Ibarz J, Sweet KL, Corrales-Yepez GM, Komrokji RS.

Onco Targets Ther. 2016 Aug 10;9:4937-57. doi: 10.2147/OTT.S102504. eCollection 2016. Review.

7.

Aberrant Promoter Hypomethylation in CLL: Does It Matter for Disease Development?

Upchurch GM, Haney SL, Opavsky R.

Front Oncol. 2016 Aug 11;6:182. doi: 10.3389/fonc.2016.00182. eCollection 2016. Review.

8.

Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.

Imai Y, Maru Y, Tanaka J.

Cancer Sci. 2016 Aug 24. doi: 10.1111/cas.13062. [Epub ahead of print] Review.

9.

Systemic Sclerosis and Malignancy: A Review of Current Data.

Zeineddine N, Khoury LE, Mosak J.

J Clin Med Res. 2016 Sep;8(9):625-32. doi: 10.14740/jocmr2606w. Epub 2016 Jul 30. Review.

10.

The Role of MicroRNAs in Myeloproliferative Neoplasia.

Alizadeh S, Azizi SG, Soleimani M, Farshi Y, Kashani Khatib Z.

Int J Hematol Oncol Stem Cell Res. 2016 Jul 1;10(3):172-85. Review.

11.

Bone Marrow Adipose Tissue: A New Player in Cancer Metastasis to Bone.

Morris EV, Edwards CM.

Front Endocrinol (Lausanne). 2016 Jul 14;7:90. doi: 10.3389/fendo.2016.00090. eCollection 2016. Review.

12.

Acute myeloid leukemia in the older adults.

Almeida AM, Ramos F.

Leuk Res Rep. 2016 Jun 16;6:1-7. doi: 10.1016/j.lrr.2016.06.001. eCollection 2016. Review.

13.

Hematologic malignancies during pregnancy: A review.

Mahmoud HK, Samra MA, Fathy GM.

J Adv Res. 2016 Jul;7(4):589-96. doi: 10.1016/j.jare.2016.02.001. Epub 2016 Feb 8. Review.

14.

Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies.

Ozoya OO, Sokol L, Dalia S.

J Clin Transl Hepatol. 2016 Jun 28;4(2):143-50. doi: 10.14218/JCTH.2016.00005. Epub 2016 Jun 15. Review.

15.

[Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].

Tovar-Bobadilla JL, Ortiz-Hidalgo C.

Gac Med Mex. 2016 May-Jun;152(3):407-18. Review. Spanish.

16.

Addendum to Haematological Cancers: Improving Outcomes (Update).

National Collaborating Centre for Cancer (UK).

London: National Institute for Health and Care Excellence (UK); 2016 May.

17.

Emerging treatment options for myelofibrosis: focus on pacritinib.

Chow V, Weissman A, O'Connell CL, Mehrvar A, Akhtari M.

Onco Targets Ther. 2016 May 4;9:2655-65. doi: 10.2147/OTT.S93875. eCollection 2016. Review.

18.

Integrating mutation variant allele frequency into clinical practice in myeloid malignancies.

Sallman DA, Padron E.

Hematol Oncol Stem Cell Ther. 2016 Sep;9(3):89-95. doi: 10.1016/j.hemonc.2016.04.003. Epub 2016 May 11. Review.

19.

Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets.

Griffioen M, van Bergen CA, Falkenburg JH.

Front Immunol. 2016 Mar 15;7:100. doi: 10.3389/fimmu.2016.00100. eCollection 2016. Review.

20.

The progress of angiogenic factors in the development of leukemias.

Han Y, Wang X, Wang B, Jiang G.

Intractable Rare Dis Res. 2016 Feb;5(1):6-16. doi: 10.5582/irdr.2015.01048. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk